title: A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
authors.affiliation: University of Massachusetts Medical School, Worcester.
authors.forename: Kristen
authors.initials: K
authors.lastname: Corey
authors.affiliation: Department of Pathology, University of Vermont College of Medicine, Burlington.
authors.forename: Deborah
authors.initials: D
authors.lastname: Cook
authors.affiliation: Department of Pathology, University of Vermont College of Medicine, Burlington.
authors.forename: Jessica
authors.initials: J
authors.lastname: Bekker
authors.affiliation: Division of Hematology/Oncology, University of Vermont College of Medicine, Burlington.
authors.forename: Emiliano
authors.initials: E
authors.lastname: Mugnaini
authors.affiliation: Division of Dermatology, University of Vermont College of Medicine, Burlington.
authors.forename: Julie H
authors.initials: JH
authors.lastname: Lin
mesh_terms: D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000473:pathology; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin